- Efficacy and Safety of TLR2 Co-Stimulated CAR T Cells in CD19-Positive Lymphoid Malignancies with Central Nervous System InvolvementHe, Bailin; Zhou, Hongsheng; Lin, Ren; Wang, Zhixiang; Xu, Na; Wang, Qiang; Sun, Jing; Liu, Xiaoli; Li, Peng; Liu, Qifa65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALLKang, Liqing; Ma, Jinfeng; Lou, Xiaoyan; Tang, Xiaowen; Xue, Shengli; Chen, Suning; Qiu, Huiying; Miao, Miao; Han, Yue; Wang, Ying; Sun, Aining; Dai, Haiping; Xu, Yang; Li, Limin; Fan, Shengjin; Qian, Chongsheng; Gong, Wenjie; Xu, Mingzhu; Zhou, Haixia; Yao, Zhen65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- MIP3α As an Early Prognostic Predictor for Patients with B-Cell Malignancies Receiving CD19/CD22-Redirected CAR T-Cell Cocktail TherapyJin, Jin; Cheng, Jiali; Wang, Na; Huang, Liang; Zhou, Xiaoxi; Chen, Liting; Luo, Hui; Liu, Tianjiao; Meng, Jiao64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA, 2022-12-10 To 2022-12-13.
期刊论文
Successful treatment of severe cytokine release syndrome after CAR-T therapy by ruxolitinib without compromising CAR-T efficacy
3被引5阅读
